Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-08-13Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) [Phase 3]
Phase 3 trial evaluating two doses of certolizumab pegol for plaque psoriasis has completed with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-08-10Clinical Trial Update: A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203) [Phase 2]
Phase 2 trial comparing 188-0551 solution to vehicle in plaque psoriasis has completed.
-
CLINICAL_TRIALS trial_result · 2018-07-23Clinical Trial Update: Natural Gels for Treatment of Plaque Psoriasis [Phase 2, Phase 3]
A clinical trial update reports Phase 2 and Phase 3 testing of Natural Gels for treating plaque psoriasis, with parapsoriasis listed as a co…
-
CLINICAL_TRIALS trial_result · 2018-07-18Clinical Trial Update: Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) [Phase 3]
Phase 3 trial assessing certolizumab pegol versus active comparator and placebo in plaque psoriasis; study completed with results posted in …
-
CLINICAL_TRIALS trial_result · 2018-07-18Clinical Trial Update: A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment [Phase 3]
Phase 3 trial update for ixekizumab in moderate-to-severe plaque psoriasis patients naive to systemic treatment; study completed with result…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-06-27Clinical Trial Update: A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) [Phase 3]
Phase 3 study evaluating subcutaneous tildrakizumab for moderate-to-severe chronic plaque psoriasis with long-term extension; trial complete…
-
CLINICAL_TRIALS trial_result · 2018-06-13Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) [Phase 3]
Phase 3 trial evaluating subcutaneous MK-3222 in moderate-to-severe chronic plaque psoriasis completed; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-06-12Clinical Trial Update: Efficacy and Safety Study of NP000888 in Subjects With Plaque and Nail Psoriasis [Phase 2]
Phase 2 efficacy and safety study of NP000888 in plaque psoriasis and nail psoriasis has completed. The provided snippet does not include ef…
-
CLINICAL_TRIALS research · 2018-06-12Clinical Trial Update: Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis [Phase 4]
Phase 4 clinical trial update on apremilast for pruritus and quality of life in scalp psoriasis; current status is unknown.
-
FDA approval · 2018-06-08FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab submitted by Janssen Biotech, Inc.
-
FDA approval · 2018-05-25FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
FDA approved a supplemental application for ENBREL (etanercept) submitted by Immunex Corporation. The approval pertains to the supplement to…
-
CLINICAL_TRIALS trial_result · 2018-05-25Clinical Trial Update: 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis [Phase 3]
This four-year extension trial reports long-term efficacy and safety of secukinumab in adults with chronic plaque psoriasis. The Phase 3 stu…
-
FDA approval · 2018-05-11FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
The FDA approved a supplemental application for ENBREL (etanercept) submitted by Immunex Corporation. The action updates the drug's labeling…
-
CLINICAL_TRIALS trial_result · 2018-05-11Clinical Trial Update: Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis [Phase 1]
Phase 1 study evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of Calcipotriene 0.005% Foam under maximal use in 12-16…
-
CLINICAL_TRIALS trial_result · 2018-04-20Clinical Trial Update: Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis [Phase 1]
Phase 1 clinical trial updating safety and efficacy of UC-MSCs (umbilical cord-derived mesenchymal stem cells) in patients with moderate to …
-
CLINICAL_TRIALS trial_result · 2018-04-18Clinical Trial Update: DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis [Phase 2]
Phase 2 study comparing DFD06 Cream to clobetasol propionate 0.05% in moderate-to-severe plaque psoriasis to evaluate HPA axis suppression; …
-
CLINICAL_TRIALS trial_result · 2018-04-18Clinical Trial Update: A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis [Phase 3]
A Phase 3 trial comparing different dosing regimens of ixekizumab (LY2439821) in adults with moderate to severe plaque psoriasis has complet…
-
FDA label_change · 2018-04-16FDA Approved: TAZORAC — Supplemental Application (Almirall, LLC)
The FDA approved a supplemental application for TAZORAC (tazarotene) from Almirall, updating the product’s labeling.
-
CLINICAL_TRIALS trial_result · 2018-04-13Clinical Trial Update: A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis [Phase 3]
This update notes the completion of a Phase 3 study assessing the efficacy and safety of DFD-06 Cream for moderate to severe plaque psoriasi…
-
CLINICAL_TRIALS trial_result · 2018-04-13Clinical Trial Update: A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis [Phase 3]
A Phase 3 study evaluated the efficacy and safety of DFD-06 Cream for moderate to severe plaque psoriasis. Results were posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-04-12Clinical Trial Update: A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis [NA]
A multicenter clinical trial evaluating 074-6751 Lotion for moderate plaque psoriasis has completed.
-
FDA approval · 2018-03-26FDA Approved: CLOBETASOL PROPIONATE — Original Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a generic clobetasol propionate topical product from Glenmark Pharmaceuticals (ANDA 209004) for treatment of inflammatory and p…
-
FDA approval · 2018-03-20FDA Approved: ILUMYA — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved ILUMYA (tildrakizumab-asmn) in an original application from Sun Pharmaceutical Industries. The approval covers its use for plaq…
-
FDA approval · 2018-03-20FDA Approved: CIMZIA — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for Cimzia (certolizumab pegol) filed by UCB, Inc.
-
FDA approval · 2018-03-15FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
FDA approved a supplemental application for AMJEVITA (adalimumab-atto) submitted by Nuvaila Limited.